Kazue Umetsu
Overview
Explore the profile of Kazue Umetsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
56
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takehara K, Koga Y, Hachisu Y, Utsugi M, Sawada Y, Saito Y, et al.
Respir Investig
. 2024 Mar;
62(3):388-394.
PMID: 38460356
Background: The antifibrotic agents pirfenidone and nintedanib have been shown to be effective in patients with idiopathic pulmonary fibrosis (IPF). However, discontinuation of antifibrotic drugs is a major clinical concern...
2.
Kubo E, Harada M, Ishizuka K, Umetsu K, Inoue Y, Kosugi K, et al.
J Palliat Med
. 2023 Nov;
26(11):1444-1445.
PMID: 37955879
No abstract available.
3.
Takehara K, Koga Y, Hachisu Y, Utsugi M, Sawada Y, Saito Y, et al.
Cells
. 2022 Jan;
11(1).
PMID: 35011705
Antifibrotic agents have been widely used in patients with idiopathic pulmonary fibrosis (IPF). Long-term continuation of antifibrotic therapy is required for IPF treatment to prevent disease progression. However, antifibrotic treatment...
4.
Yamaguchi K, Yamaguchi A, Itai M, Onuki Y, Shin Y, Uno S, et al.
Rheumatol Int
. 2021 May;
41(9):1641-1650.
PMID: 34056682
Anti-neutrophil cytoplasmic antibodies-associated vasculitis (AAV) occurs in elderly people, and patients with anti-myeloperoxidase autoantibodies (MPO-ANCA)-positive AAV are often complicated with interstitial lung disease (ILD). This study aimed to evaluate the...
5.
Takemura M, Motegi M, Kuroiwa Y, Itai M, Taguchi K, Umetsu K, et al.
Respir Med Case Rep
. 2021 Mar;
32:101361.
PMID: 33643837
A 67-year-old man with stage IV B lung adenocarcinoma was treated with pembrolizumab. The patient was admitted to the hospital because of influenza on the day of the second cycle...
6.
Yamaguchi K, Yamaguchi A, Onuki Y, Itai M, Kashiwagi C, Takehara K, et al.
Mod Rheumatol
. 2020 Mar;
31(1):177-185.
PMID: 32149542
Objectives: Anti-melanoma differentiation-associated gene 5 (MDA5) autoantibody-positive and age at onset ≥60 years are poor prognosis factors in polymyositis (PM) and dermatomyositis (DM) associated with interstitial lung disease (ILD) among...
7.
Yamaguchi K, Yamaguchi A, Itai M, Kashiwagi C, Takehara K, Aoki S, et al.
Clin Rheumatol
. 2019 Aug;
38(12):3443-3450.
PMID: 31420814
Background: Dermatomyositis (DM) with autoantibody against melanoma differentiation-associated gene-5 (MDA5) is characterized by elevated risk of rapidly progressive interstitial lung disease (RP-ILD) with a potentially fatal course. Pneumomediastinum (PNM) is...
8.
Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, et al.
Respir Med
. 2018 Jun;
140:1-5.
PMID: 29957268
Background: Anti-melanoma differentiation-associated gene 5 (MDA5) autoantibodies have been identified as myositis-specific autoantibodies that are often associated with clinically amyopathic dermatomyositis (CADM) and a poor prognosis due to rapidly progressive...